Dexamethasone Sp label

Dexamethasone Sp

Dexamethasone Sp Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

WARNINGS:

Clinical and experimental data have demonstrated that corticosteroids administered orally or by injection to animals may induce the first stage of parturition if used during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis.  Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have produced cleft palate.  Other congenital anomalies including deformed forelegs, phocomelia, and anasarca have been reported in offspring of dogs which received corticosteroids during pregnancy.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

INDICATIONS AND USAGE:

Dexamethasone Sodium Phosphate Injection is indicated as a rapid adrenal glucocorticoid and/or anti-inflammatory agent in horses.

History

There is currently no drug history available for this drug.

Other Information


DESCRIPTION

Dexamethasone sodium phophate (a synthetic adrenocortical steroid), is a white or slightly yellow crystalline powder.  It is freely soluble in water and is exceedingly hygroscopic.  Each mL of sterile aqueous solution contains Dexamethasone Sodium Phosphate 4 mg (equivalent to dexamethasone 3 mg), Sodium Citrate 10 mg, Sodium Bisulfate 2 mg, Benzyl Alcohol 1.5% as a preservative, in Water for Injection q.s. Sodium Hydroxide and/or Hydrochloric Acid to adjust pH to between 7.0 and 8.5.

Dexamethasone Sp Manufacturers

  • Mwi/vetone
    Dexamethasone Sp | Mwi/vetone
    No Recall

    Dexamethasone Sp | Mwi/vetone

    Dexamethasone Sp | Mwi/vetone

    DOSAGE AND ADMINISTRATION:  For Intravenous Use Only.

    Horses:  The usual intravenous dosage is 2.5 to 5 mg (based on 3 mg per mL of dexamethasone content).

    If permanent corticosteroid effect is required, oral therapy with dexamethasone may be substituted.  When therapy is to be withdrawn after prolonged corticosteroid administration, the daily dose should be reduced gradually over a number of days, in stepwise fashion.